Products
Mometasone nasal spray has been approved in many countries since 1997 (Nasonex, generics). Generic products were approved in 2012 and entered the market in 2013. Mometasone furoate is also used for the treatment of skin conditions and asthma see Mometasone and Mometasone Inhalation.
Structure and properties
Mometasone (C22H28Cl2O4, Mr = 427.4 g/mol) is present in the drug as mometasone furoate, a white powder that is practically insoluble in water. It is a furan derivative and a chlorinated glucocorticoid.
Effects
Mometasone furoate (ATC R01AD09) has potent anti-inflammatory, antiallergic, and immunosuppressive properties. The effects are due to binding to the intracellular glucocorticoid receptor.
Indications
For the treatment of seasonal and chronic perennial allergic rhinitis, nasal polyps, and acute sinusitis. Self-medication: symptomatic treatment of seasonal allergic rhinitis in adults after initial medical diagnosis.
Dosage
According to the prescribing information. Nasal spray should be administered regularly once or twice daily for optimal efficacy. Shake well before use!
Contraindications
The spray is contraindicated in case of hypersensitivity. In self-medication, use is not indicated in patients under 18 years of age. For complete precautions, see the drug label.
Interactions
Mometasone furoate is metabolized in the liver by CYP3A4. Strong CYP inhibitors such as ketoconazole may increase plasma concentrations.
Adverse effects
The most common potential adverse effects include nosebleeds; inflammation of the throat; burning, irritation, and ulceration of the nose; and headache.